Heparin-associated thrombocytopenia treatment with low molecular weight heparin.
Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.
Vitoux
J F
JF
Mathieu
J F
JF
Roncato
M
M
Fiessinger
J N
JN
Aiach
M
M
D000368:Aged; D001792:Blood Platelets / Q000276:immunology; D005260:Female; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy
D007074:Immunoglobulin G; D006493:Heparin